Skip to content
10-Q

Quarterly Report

Whitehawk Therapeutics, Inc. WHWK

0001628280-25-023932

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 2, 2025 47.11M sh
Short Term Investments Q1 2025 · Mar 31, 2025 $3.49M
Short Term Investments Q1 2025 · Dec 31, 2024 $18.57M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $227.57M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $28.67M
Current Liabilities Q1 2025 · Mar 31, 2025 $12.27M
Current Liabilities Q1 2025 · Dec 31, 2024 $17.07M
Total Liabilities Q1 2025 · Mar 31, 2025 $12.27M
Total Liabilities Q1 2025 · Dec 31, 2024 $17.84M
Current Assets Q1 2025 · Mar 31, 2025 $232.61M
Current Assets Q1 2025 · Dec 31, 2024 $61.29M
Total Assets Q1 2025 · Mar 31, 2025 $234M
Total Assets Q1 2025 · Dec 31, 2024 $70.32M
Shares Diluted Q1 2025 · Mar 31, 2024 26.98M sh
Capex Q1 2025 · Mar 31, 2024 $739K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$19.65M
Stockholders Equity Q1 2025 · Mar 31, 2024 $90.46M
Stockholders Equity Q1 2025 · Dec 31, 2023 $105.2M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.68
Eps Basic Q1 2025 · Mar 31, 2024 −$0.68
Sga Expense Q1 2025 · Mar 31, 2024 $10.62M
Rd Expense Q1 2025 · Mar 31, 2024 $13.59M
Net Income Q1 2025 · Mar 31, 2024 −$18.29M
Operating Income Q1 2025 · Mar 31, 2024 −$19.51M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $652K
Revenue Q1 2025 · Mar 31, 2024 $5.35M